HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis

Journal of Infectious Diseases

Volumn 195, Issue 2, 2007, Pages 236-245

  Barat, Corinne ^a   Zhao, Chenqi ^a   Ouellette, Marc ^a   Tremblay, Michel J ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MEGLUMINE ANTIMONATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PICEATANNOL; PROTEIN KINASE SYK; SC 68376; STIBOGLUCONATE SODIUM; STRESS ACTIVATED PROTEIN KINASE; TACROLIMUS; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; CD4+ T LYMPHOCYTE; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LEISHMANIASIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYMUS; TISSUE CULTURE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION;

ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV-1; HUMANS; LEISHMANIASIS; LEUKOCYTES, MONONUCLEAR; ORGAN CULTURE TECHNIQUES; THYMUS GLAND; TRANSCRIPTION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 33846121304     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510398     Document Type: Article

References (36)

1. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97(Suppl 1):3-15.
2. Zhao C, Papadopoulou B, Tremblay MJ. Leishmania infantum enhances human immunodeficiency virus type-1 replication in primary human macrophages through a complex cytokine network. Clin Immunol 2004; 113:81-8.
3. Zhao C, Papadopoulou B, Tremblay MJ. Leishmania infantum promotes replication of HIV type 1 in human lymphoid tissue cultured ex vivo by inducing secretion of the proinflammatory cytokines TNF-alpha and IL-1 alpha. J Immunol 2004; 172:3086-93.
4. Medrano FJ, Rey C, Leal M, et al. Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Clin Exp Immunol 1998; 114:403-7.
5. Cacopardo B, Nigro L, Preiser W, et al. Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment. Trans R Soc Trop Med Hyg 1996; 90:434-5.
6. Olivier M, Badaro R, Medrano FJ, Moreno J. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 2003; 97(Suppl 1):79-98.
7. Russo R, Laguna F, Lopez-Velez R, et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 2003; 97(Suppl 1):99-105.
8. Berhe N, Wolday D, Hailu A, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999; 13: 1921-5.
9. Moreno J, Canavate C, Chamizo C, Laguna F, Alvar J. HIV-Leishmania infantum co-infection: humoral and cellular immune responses to the parasite after chemotherapy. Trans R Soc Trop Med Hyg 2000; 94:328-32.
10. Ribera E, Ocana I, de Otero J, Cortes E, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100:496-501.
11. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97(Suppl 1):135-42.
12. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
13. Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004; 71:787-94.
14. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 2001; 167:3391-7.
15. Barbeau B, Bernier R, Dumais N, et al. Activation of HIV-1 long terminal repeat transcription and virus replication via NF-κB-dependent and -independent pathways by potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds. J Biol Chem 1997; 272:12968-77.
16. Keir ME, Stoddart CA, Linquist-Stepps V, Moreno ME, McCune JM. IFN-alpha secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus. J Immunol 2002; 168:325-31.
17. Martin PJ, Ledbetter JA, Morishita Y, June CH, Beatty PG, Hansen JA. A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J Immunol 1986; 136:3282-7.
18. Yee JK, Friedmann T, Burns JC. Generation of high-liter pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994; 43:99-112.
19. +-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 2002; 76:1004-14.
20. Barat C, Tremblay MJ. Engagement of CD43 enhances human immunodeficiency virus type 1 transcriptional activity and virus production that is induced upon TCR/CD3 stimulation. J Biol Chem 2002; 277:28714-24.
21. Roberts WL, Berman JD, Rainey PM. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 1995; 39:1234-9.
22. Roy J, Audette M, Tremblay MJ. Intercellular adhesion molecule-1 (ICAM-1) gene expression in human T cells is regulated by phosphotyrosyl phosphatase activity. Involvement of NF-κB, Ets, and palindromic interferon-γ- responsive element-binding sites. J Biol Chem 2001; 276:14553-61.
23. Castellanos MC, Munoz C, Montoya MC, Lara-Pezzi E, Lopez-Cabrera M, de Landazuri MO. Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1. J Immunol 1997; 159:5463-73.
24. 2 regulates the activation of distinct MAPK pathways. Free Radic Biol Med 2002; 33: 1121-32.
25. Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 2003; 4:248-54.
26. Mookerjee Basu J, Mookerjee A, Sen P, et al. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 2006; 50:1788-97.
27. Pathak MK, Hu X, Yi T. Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. Leukemia 2002; 16:2285-91.
28. Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC. Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol 2002; 169:5978-85.
29. Poli G. Cytokines and chemokines in HIV infection. In: Pantaleo G, Walker BD, eds. Retroviral immunology: immune response and restoration. Totowa, NJ: Humana Press, 2001:53-78.
30. Hildreth JE, Orentas RJ. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 1989; 244:1075-8.
31. Pantaleo G, Butini L, Graziosi C, et al. Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. J Exp Med 1991; 173:511-4.
32. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 1988; 82:69-72.
33. Jaser MA, el-Yazigi A, Croft SL. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm Res 1995; 12:113-6.
34. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
35. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43:357-64.
36. Delgado J, Macias J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 1999; 61:766-9.